| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| CDT Equity Inc. | AZD1656 | Renal Transplant | Phase 2 | Trial Planned | oral | Immunosuppressant |
| CDT Equity Inc. | AZD1656 | Hashimoto’s Thyroiditis | Phase 2 | Trial Planned | oral | Endocrinology |
| CDT Equity Inc. | AZD1656 | Uveitis | Phase 2 | Trial Planned | oral | Opthalmic |
| CDT Equity Inc. | AZD1656 | Preterm Labor | Phase 2 | Trial Planned | oral | Women's Health |
| Celcuity Inc. | VIZIMPRO (dacomitinib) and XALKORI (crizotinib) - (FACT-3) | HER2-negative breast cancer | Phase 2 | Trial Discontinued | Oral | Oncology |
| Celcuity Inc. | NERLYNX (neratinib) and Xeloda (capecitabine) | HER2-negative breast cancer | Phase 2 | Trial Planned | Oral | Oncology |
| Celcuity Inc. | TABRECTA (capmatinib) and NERLYNX (Neratinib) - (FACT-5) | HER2-negative breast cancer | Phase 2 | Trial Planned | Oral | Oncology |
| Celcuity Inc. | NERLYNX (neratinib) and FASLODEX (fulvestrant) - (FACT-4) | HR-positive, HER2-negative breast cancer | Phase 2 | Trial Planned | NERLYNX oral FASLODEX intramuscular | Oncology |